EXACT Sciences Corp (EXAS)

[TREND1]

The Exact Sciences team delivered another strong quarter with $73 million in revenue, 161,000 completed Cologuard tests and more than 10,000 new ordering physicians and other healthcare providers. The growth and enthusiasm of our patient and physician customer bases are helping us begin to achieve our goal of making Cologuard the standard of care in colon cancer screening.

Third quarter cash use totaled $21.7 million. Adjusting for the MDxHealth payment in the second quarter, cash use improved by $7.1 million on better-than-expected operating results and some working capital benefits. We ended the quarter with cash and marketable securities of $462.5 million.